Table 1 Demographic, laboratory, and clinical characteristics of the studied patients
n Mean ± Std. dev. | % Median (IQR) | |
|---|---|---|
Gender | ||
Male | 58 | 66.7 |
Female | 29 | 33.3 |
Age, years (n = 87) | 62.5 ± 16.2 | 61 (24) |
Presence of any comorbidity | 59 | 67.8 |
Malignancy | 12 | 13.8 |
COVID-19 diagnosis method | ||
SARS-CoV-2 PCR | 59 | 67.8 |
Radiological examination (thoracic CT) | 28 | 32.2 |
Presence of pneumonia | 69 | 79.3 |
Presence of deep vein thrombosis | 20 | 23 |
Echocardiogram findings | ||
Tricuspid valve regurgitation grade (n = 28) | 1.46 ± 0.77 | 1.00 (1.00) |
Pulmonary artery pressure (mmHg) (n = 29) | 40.5 ± 12.9 | 38.0 (20.0) |
PESI score (n = 87) | 93.4 ± 15.1 | 17.0 (21.0) |
PESI class | ||
I | 21 | 24.1 |
II | 21 | 24.1 |
III | 13 | 14.9 |
IV | 15 | 17.2 |
V | 17 | 19.5 |
Total simplified Mastora score (n = 87) | 19.5 ± 15.18 | 17.0 (21.0) |
Early mortality risk groups | ||
Low | 53 | 60.9 |
Intermediate-low | 18 | 20.7 |
Intermediate-high/high | 16 | 18.4 |
Laboratory findings | ||
Lymphocyte leucocytes (/µL) (n = 79) | 1194.0 ± 748.6 | 1100 (1010) |
Neutrophil/lymphocyte ratio (n = 76) | 7.59 ± 7.65 | 5.65 (6.27) |
Interleukin-6 (pg/ml) (n = 24) | 28.5 ± 33.3 | 15.1 (24.8) |
Troponin (ng/L) (n = 76) | 48.0 ± 135.1 | 9.0 (29.0) |
D-dimer (mg/L) (n = 72) | 9.5 ± 10.3 | 5.3 (12.0) |
Brain natriuretic peptide (ng/L) (n = 20) | 2614 ± 5035 | 331 (1412) |
Concurrent pulmonary embolism | 37 | 42.5 |
Post-COVID-19 pulmonary embolism | 50 | 57.5 |
Deceased | 10 | 11.5 |